Duopharma poised for a re-rating

Duopharma is seen as a proven defensive shelter amid financial and economic uncertainties.

PETALING JAYA: As the Covid-19 pandemic hype diminishes, Duopharma Biotech Bhd’s strong execution and consistent earnings growth should eventually lead to a re-rating.

Duopharma is seen as a proven defensive shelter amid financial and economic uncertainties.

Get 30% off with our ads free Premium Plan!

Monthly Plan

RM13.90/month
RM9.73 only

Subscribe

Billed as RM9.73 for the 1st month then RM13.90 thereafters.

Annual Plan

RM12.33/month
RM8.63/month

Subscribe

Billed as RM103.60 for the 1st year then RM148 thereafters.

1 month

Free Trial

For new subscribers only

Subscribe
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Duopharma , re-rating , budget ,

   

Report it to us.

Next In Business News
Ports powering property
Smart homes on a budget
Tackling the complexities of flooding
Ringgit to exhibit softness in thin trading next week
Stay the course in Malaysia’s growth
Bond option for retirees
Raising The Standard in Singapore
Slow going for O&G
What 2025 means to the economy
Government to decide on new electricity tariffs

Trending in Business

Others Also Read

Load more

Copyright © 1995- Star Media Group Berhad [197101000523 (10894-D)]

Best viewed on Chrome browsers.